PAX-8 Expression in Salivary Duct Carcinoma.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
received:
19
01
2021
accepted:
04
05
2021
pubmed:
4
6
2021
medline:
8
3
2022
entrez:
3
6
2021
Statut:
ppublish
Résumé
Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma resembling breast ductal carcinoma. It accounts for ~10% of malignant tumors of the salivary glands. Most cases show expression of CK7 and androgen receptor. PAX-8 is a transcription factor, with expression reported in renal, Müllerian, and thyroid carcinomas. Previous studies have described an absence of PAX-8 immunostaining in most primary salivary gland neoplasms, including SDCs. However, PAX-8 expression is frequently found in neoplasms that can metastasize to salivary glands, suggesting the possibility that this protein can be used to differentiate SDC from secondary neoplastic involvement of the salivary gland. We evaluated the expression of PAX-8 in 14 cases of SDC from our institution. One case showed diffuse moderate to strong PAX-8 positivity, while 2 tumors showed focal weak staining. Therefore, we conclude that although the majority of SDC are negative for PAX-8, rare diffuse positivity can be seen in these primary salivary gland tumors. This could potentially pose difficulty in ruling out metastatic disease from another PAX-8-positive primary neoplasm.
Identifiants
pubmed: 34081633
doi: 10.1097/PAI.0000000000000951
pii: 00129039-202110000-00007
doi:
Substances chimiques
Neoplasm Proteins
0
PAX8 Transcription Factor
0
PAX8 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
680-684Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005;103:2526–2533.
McHugh JB Goldblum J, Lamps L, McKenney J, Myers J. Major and minor salivary glands. Rosai and Ackerman’s Surgical Pathology, 11th ed. Philadelphia, PA: Elsevier; 2018:235–268.
Sartorius C, Gille F, Bédrossian-Pfingsten J, et al. Salivary duct carcinoma of the sublingual gland-a case report. Laryngorhinootologie. 2006;85:517–519.
Takeda Y, Yamamoto H. Oral collision carcinoma: salivary duct carcinoma of minor salivary gland origin and squamous cell carcinoma of the oral mucosa. J Oral Sci. 1999;41:129–131.
Jeong HS, Son YI, Ko YH, et al. Sarcomatoid salivary duct carcinoma of the larynx. J Laryngol Otol. 2006;120:154–157.
Higo R, Takahashi T, Nakata H, et al. Salivary duct carcinoma in the sinonasal tract. Eur Arch Otorhinolaryngol. 2007;264:561–563.
Wick MR, Ockner DM, Mills SE, et al. Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol. 1998;109:75–84.
Moutasim KA, Thomas GJ. Salivary gland tumours: update on molecular diagnostics. Diagn Histopathol. 2020;26:159–164.
Simpson RH, Prasad AR, Lewis JE, et al. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27:1070–1079.
Thompson LD. Salivary duct carcinoma. Ear Nose Throat J. 2012;91:356–359.
Schwartz LE, Begum S, Westra WH, et al. GATA3 immunohistochemical expression in salivary gland neoplasms. Head Neck Pathol. 2013;7:311–315.
Zhu S, Schuerch C, Hunt J. Review and updates of immunohistochemistry in selected salivary gland and head and neck tumors. Arch Pathol Lab Med. 2015;139:55–66.
Williams L, Thompson LD, Seethala RR, et al. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol. 2015;39:705–713.
Skálová A, Stárek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2003;42:348–356.
Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816–826.
Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24:751–764.
Butler RT, Alderman MA, Thompson LD, et al. Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms. Head Neck Pathol. 2015;9:47–50.
Xiang L, Kong B. PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomas. Oncol Lett. 2013;5:735–738.
Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 2002;18:41–47.
Lu H, Allende D, Liu X, et al. Lymphoid enhancer binding factor 1 (LEF1) and paired box gene 8 (PAX8): a limited immunohistochemistry panel to distinguish solid pseudopapillary neoplasms and pancreatic neuroendocrine tumors. Appl Immunohistochem Mol Morphol. 2020;28:776–780.
Sangoi AR, Ohgami RS, Pai RK, et al. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24:412–424.
Long KB, Srivastava A, Hirsch MS, et al. PAX8 expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010;34:723–729.
Chinchilla-Tábora LM, Ortiz Rodríguez-Parets J, González Morais I, et al. Immunohistochemical analysis of CD99 and PAX8 in a series of 15 molecularly confirmed cases of Ewing sarcoma. Sarcoma. 2020;2020:3180798.
Singh K, Hanley LC, Sung CJ, et al. Comparison of PAX8 expression in breast carcinoma using MRQ50 and BC12 monoclonal antibodies. Appl Immunohistochem Mol Morphol. 2020;28:558–561.
Lu S, Yakirevich E, Hart J, et al. PAX8 expression in breast cancer. Appl Immunohistochem Mol Morphol. 2021;29:293–298.
Kilgore MR, Bosch DE, Adamson KH, et al. Unexpected PAX8 immunoreactivity in metastatic high-grade breast cancer. Appl Immunohistochem Mol Morphol. 2019;27:637–643.
Seifert G, Hennings K, Caselitz J. Metastatic tumors to the parotid and submandibular glands-analysis and differential diagnosis of 108 cases. Pathol Res Pract. 1986;181:684–692.
Batsakis JG, Bautina E. Metastases to major salivary glands. Ann Otol Rhinol Laryngol. 1990;99(pt 1)501:503.
McHugh JB, Hoschar AP, Dvorakova M, et al. p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head Neck Pathol. 2007;1:123–131.
Barr ML, Jilaveanu LB, Camp RL, et al. PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?. J Clin Pathol. 2015;68:12–17.
Ozcan A, de la Roza G, Ro JY, et al. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison. Arch Pathol Lab Med. 2012;136:1541–1551.
Selves J, Long-Mira E, Mathieu MC, et al. Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers. 2018;10:108.